Efficacy and safety of shorter multidrug-resistant or rifampicin-resistant tuberculosis regimens: a network meta-analysis.
Multidrug-resistant tuberculosis (MDR-TB)
Network meta-analysis
Rifampicin-resistant tuberculosis (RR-TB)
Short- term regimens
Systematic review
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
01 Oct 2024
01 Oct 2024
Historique:
received:
30
11
2023
accepted:
19
09
2024
medline:
2
10
2024
pubmed:
2
10
2024
entrez:
1
10
2024
Statut:
epublish
Résumé
Drug-resistant tuberculosis (DR-TB) remains a threat to public health. Shorter regimens have been proposed as potentially valuable treatments for multidrug or rifampicin resistant tuberculosis (MDR/RR-TB). We undertook a systematic review and network meta-analysis to evaluate the efficacy and safety of shorter MDR/RR-TB regimens. We searched PubMed/MEDLINE, Cochrane Center for Clinical Trials (CENTRAL), Scopus, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, US Food and Drug Administration, and Chinese Clinical Trial Registry for primary articles published from 2013 to July 2023. Favorable (cured and treatment completed) and unfavorable (treatment failure, death, loss to follow-up, and culture conversion) outcomes were assessed as the main efficacy outcomes, while adverse events were assessed as the safety outcomes. The network meta-analysis was performed using R Studio version 4.3.1 and the Netmeta package. The study protocol adhered to the PRISMA-NMA guidelines and was registered in PROSPERO (CRD42023434050). We included 11 eligible studies (4 randomized control trials and 7 cohorts) that enrolled 3,548 patients with MDR/RR-TB. Treatment with a 6-month combination of BdqLzdLfxZTrd/Eto/H had two times more favorable outcomes [RR 2.2 (95% CI 1.22, 4.13), P = 0.0094], followed by a 9-11 month combination of km/CmMfx/LfxPtoCfzZEHh [RR1.67 (95% CI 1.45, 1.92), P < 0.001] and a 6-month BdqPaLzdMfx [RR 1.64 (95% CI 1.24, 2.16), P < 0.0005] compared to the standard longer regimens. Treatment with 6 months of BdqPaLzdMfx [RR 0.33 (95% CI 0.2, 0.55), P < 0.0001] had a low risk of severe adverse events, followed by 6 months of BdqPaLzd [RR 0.36 (95% CI 0.22, 0.59), P ≤ 0.001] and BdqPaLzdCfz [RR 0.54 (95% CI 0.37, 0.80), P < 0.0001] than standard of care. Treatment of patients with RR/MDR-TB using shorter regimens of 6 months BdqLzdLfxZTrd/Eto/H, 9-11 months km/CmMfx/LfxPtoCfzZEHh, and 6 months BdqPaLzdMfx provides significantly higher cure and treatment completion rates compared to the standard longer MDR/RR-TB. However, 6BdqPaLzdMfx, 6BdqPaLzd, and 6BdqPaLzdCfz short regimens are significantly associated with decreased severity of adverse events. The findings are in support of the current WHO-recommended 6-month shorter regimens.
Sections du résumé
BACKGROUND
BACKGROUND
Drug-resistant tuberculosis (DR-TB) remains a threat to public health. Shorter regimens have been proposed as potentially valuable treatments for multidrug or rifampicin resistant tuberculosis (MDR/RR-TB). We undertook a systematic review and network meta-analysis to evaluate the efficacy and safety of shorter MDR/RR-TB regimens.
METHODS
METHODS
We searched PubMed/MEDLINE, Cochrane Center for Clinical Trials (CENTRAL), Scopus, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, US Food and Drug Administration, and Chinese Clinical Trial Registry for primary articles published from 2013 to July 2023. Favorable (cured and treatment completed) and unfavorable (treatment failure, death, loss to follow-up, and culture conversion) outcomes were assessed as the main efficacy outcomes, while adverse events were assessed as the safety outcomes. The network meta-analysis was performed using R Studio version 4.3.1 and the Netmeta package. The study protocol adhered to the PRISMA-NMA guidelines and was registered in PROSPERO (CRD42023434050).
RESULT
RESULTS
We included 11 eligible studies (4 randomized control trials and 7 cohorts) that enrolled 3,548 patients with MDR/RR-TB. Treatment with a 6-month combination of BdqLzdLfxZTrd/Eto/H had two times more favorable outcomes [RR 2.2 (95% CI 1.22, 4.13), P = 0.0094], followed by a 9-11 month combination of km/CmMfx/LfxPtoCfzZEHh [RR1.67 (95% CI 1.45, 1.92), P < 0.001] and a 6-month BdqPaLzdMfx [RR 1.64 (95% CI 1.24, 2.16), P < 0.0005] compared to the standard longer regimens. Treatment with 6 months of BdqPaLzdMfx [RR 0.33 (95% CI 0.2, 0.55), P < 0.0001] had a low risk of severe adverse events, followed by 6 months of BdqPaLzd [RR 0.36 (95% CI 0.22, 0.59), P ≤ 0.001] and BdqPaLzdCfz [RR 0.54 (95% CI 0.37, 0.80), P < 0.0001] than standard of care.
CONCLUSION
CONCLUSIONS
Treatment of patients with RR/MDR-TB using shorter regimens of 6 months BdqLzdLfxZTrd/Eto/H, 9-11 months km/CmMfx/LfxPtoCfzZEHh, and 6 months BdqPaLzdMfx provides significantly higher cure and treatment completion rates compared to the standard longer MDR/RR-TB. However, 6BdqPaLzdMfx, 6BdqPaLzd, and 6BdqPaLzdCfz short regimens are significantly associated with decreased severity of adverse events. The findings are in support of the current WHO-recommended 6-month shorter regimens.
Identifiants
pubmed: 39354416
doi: 10.1186/s12879-024-09960-3
pii: 10.1186/s12879-024-09960-3
doi:
Substances chimiques
Rifampin
VJT6J7R4TR
Antitubercular Agents
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1087Informations de copyright
© 2024. The Author(s).
Références
Global tuberculosis report 2023.World Health Organization. 2023. https://www.who.int/publications-detail-redirect/9789240083851 . Cited 2023 Nov 13.
Migliori GB, Tiberi S. WHO drug-resistant TB guidelines 2022: what is new? Int J Tuberc Lung Dis. 2022;26(7):590–1.
doi: 10.5588/ijtld.22.0263
pubmed: 35768917
Organization WH. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment. In: WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment. 2022.
WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization. 2019. In. https://www.ncbi.nlm.nih.gov/books/NBK539518/table/ch1.tab2/ .
Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. Evans C, editor. PLoS Med. 2012;9(8):e1001300.
doi: 10.1371/journal.pmed.1001300
pubmed: 22952439
World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis − 2011 update. 2011;(WHO/HTM/TB/2011.6). Available from: https://apps.who.int/iris/handle/10665/44597 . Cited 2023 Jul 16.
World Health Organization. Global Tuberculosis Report 2016. Geneva: World Health, Organization. 2016. - Google Search. https://www.google.com/search?client=firefox-b-d&q=World+Health+Organization.+Global+Tuberculosis+Report+2016.+Geneva%3A+World+Health+Organization%2C+2016 . Cited 2023 Jul 16.
Bloss E, Kuksa L, Holtz TH, Riekstina V, Skripconoka V, Kammerer S, et al. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000–2004. Int J Tuberc Lung Dis off J Int Union Tuberc Lung Dis. 2010;14(3):275–81.
Nathanson E, Gupta R, Huamani P, Leimane V, Pasechnikov AD, Tupasi TE, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis off J Int Union Tuberc Lung Dis. 2004;8(11):1382–4.
Mahardani PN, Wati DK, Siloam A, Savitri NPA, Manggala AK. Effectiveness and safety of short-term regimen for Multidrug-resistant tuberculosis treatment: a systematic review of ohort studies. Oman Med J. 2022;37(1):e337–337.
doi: 10.5001/omj.2021.64
pubmed: 35211341
Von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V, Ticona E, Segura P, et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med. 2019;7(3):249–59.
doi: 10.1016/S2213-2600(18)30426-0
NCT03086486. Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix). 2017. https://clinicaltrials.gov/show/NCT03086486 . Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01562771/full .
Lee M, Mok J, Kim DK, Shim TS, Koh WJ, Jeon D, et al. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (treatment shortening of MDR-TB using existing and New drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Trials. 2019;20(1):57.
doi: 10.1186/s13063-018-3053-1
pubmed: 30651149
Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, Bonnet M, et al. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials. 2021;22(1). Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02321533/full .
Bouton TC, Phillips PPJ, Mitnick CD, Peloquin CA, Eisenach K, Patientia RF, et al. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial. Trials. 2017;18(1):563.
doi: 10.1186/s13063-017-2292-x
pubmed: 29178937
Weng T, Sun F, Li Y, Chen J, Chen X, Li R, et al. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial. BMC Infect Dis. 2021;21(1):183.
doi: 10.1186/s12879-021-05870-w
pubmed: 33596848
Rossato Silva D, Carvalho De Queiroz Mello F, Battista Migliori G. Shortened tuberculosis treatment regimens: what is new? J Bras Pneumol. 2020;46(2):e20200009–20200009.
doi: 10.36416/1806-3756/e20200009
Berry C, du Cros P, Fielding K, Gajewski S, Kazounis E, McHugh T, et al. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis. Trials. 2022;23(1):484.
doi: 10.1186/s13063-022-06331-8
pubmed: 35698158
pmcid: 9190445
Nyang’wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. A 24-Week, all-oral regimen for Rifampin-resistant tuberculosis. N Engl J Med. 2022;387(25):2331–43.
doi: 10.1056/NEJMoa2117166
pubmed: 36546625
Conradie F, Everitt D, Olugbosi M, Wills G, Fabiane S, Timm J et al. High rate of successful outcomes treating highly resistant TB in the ZeNix study of pretomanid, bedaquiline and alternative doses and durations of linezolid. J Int AIDS Soc. 2021;24(SUPPL 4). https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02348434/full .
Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al. Bedaquiline–Pretomanid–Linezolid regimens for drug-resistant tuberculosis. N Engl J Med. 2022;387(9):810–23.
doi: 10.1056/NEJMoa2119430
pubmed: 36053506
Esmail A, Oelofse S, Lombard C, Perumal R, Mbuthini L, Goolam Mahomed A, et al. An all-oral 6-month regimen for multidrug-resistant tuberculosis: a multicenter, randomized controlled clinical trial (the NExT Study). Am J Respir Crit Care Med. 2022;205(10):1214–27.
doi: 10.1164/rccm.202107-1779OC
pubmed: 35175905
Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, et al. A trial of a shorter regimen for Rifampin-resistant tuberculosis. N Engl J Med. 2019;380(13):1201–13.
doi: 10.1056/NEJMoa1811867
pubmed: 30865791
Mok J, Lee M, Kim DK, Kim JS, Jhun BW, Jo KW, et al. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea. Lancet. 2022;400(10362):1522–30.
doi: 10.1016/S0140-6736(22)01883-9
pubmed: 36522208
Du Y, Qiu C, Chen X, Wang J, Jing W, Pan H, et al. Treatment outcome of a shorter regimen containing clofazimine for multidrug-resistant tuberculosis: a randomized control trial in China. Clin Infect Dis. 2020;71(4):1047–54.
doi: 10.1093/cid/ciz915
pubmed: 31549147
Hassane-Harouna S, Cherif GF, Ortuno-Gutierrez N, Cisse D, Camara LM, Diallo BD, et al. Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: a retrospective cohort study. Ehtesham HS, editor. PLOS ONE. 2020;15(8):e0237355.
doi: 10.1371/journal.pone.0237355
pubmed: 32776969
Du Cros P, Khamraev A, Lister D, Ronnachit A, Berry C, Greig J, Parpieva N, Tillyashaykhov M, Cooke G, Dietrich S, Pylypenko T, Tigay Z, Achar J. (n.d.). Comparing shorter with conventional MDR-TB treatment in Uzbekistan: 2-month culture-conversion rates and treatment outcomes. https://d1hiluowqo0t4b.cloudfront.net/posters/docs/f1000research-164246.pdf [Accessed 7 Oct 2023].
Mleoh L, Mziray SR, Tsere D, Koppelaar I, Mulder C, Lyakurwa D. Shorter regimens improved treatment outcomes of multidrug-resistant tuberculosis patients in Tanzania in 2018 cohort. Trop Med Int Health. 2023;28(5):357–66.
doi: 10.1111/tmi.13867
pubmed: 36864011
Myemba DT, Bwire GM, Sambayi G, Maganda BA, Njiro BJ, Ndumwa HP, et al. Clinical characteristics and treatment outcomes of patients with MDR Tuberculosis in Dar Es Salaam region, Tanzania. JAC-Antimicrob Resist. 2020;2(4):dlaa108.
doi: 10.1093/jacamr/dlaa108
pubmed: 34223058
Wahid A, Ghafoor A, Khan AW, Al-Worafi YM, Latif A, Shahwani NA, et al. Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country. Front Pharmacol. 2022;13:973713.
doi: 10.3389/fphar.2022.973713
pubmed: 36160454
Zhdanova E, Goncharova O, Davtyan H, Alaverdyan S, Sargsyan A, Harries AD, et al. 9–12 months short treatment for patients with MDR-TB increases treatment success in Kyrgyzstan. J Infect Dev Ctries. 2021;15(091):S66–74.
doi: 10.3855/jidc.13757
Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–84.
doi: 10.7326/M14-2385
pubmed: 26030634
Division of Acquired Immunodeficiency Syndrome, National Institute of Allergy and Infectious Diseases National Institutes of Health, US Department of Health and Human Services. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. Vol. corrected version 2.1. 2017. Available from: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf .
World Health Organization. Definitions and reporting framework for tuberculosis – 2013 revision: updated December 2014 and January 2020. Définitions et cadre de notification pour la tuberculose – révision 2013. Geneva: World Health Organization; 2013. Available from: https://iris.who.int/handle/10665/79199 . Cited 5 Jul 2024.
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. editors. Cochrane Handbook for Systematic Reviews of Interventions. 1st ed. Wiley; 2019. https://onlinelibrary.wiley.com/doi/book/10.1002/9781119536604 . Cited 2023 Jul 27.
Sterne JAC, Hernán MA, McAleenan A, Reeves BC, Higgins JPT. Chapter 25: Assessing risk of bias in a non-randomized study. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). Cochrane, 2023. www.training.cochrane.org/handbook
Efthimiou O, Mavridis D, Debray TPA, Samara M, Belger M, Siontis GCM, et al. Combining randomized and non-randomized evidence in network meta‐analysis. Stat Med. 2017;36(8):1210–26.
doi: 10.1002/sim.7223
pubmed: 28083901
Hatami H, Sotgiu G, Bostanghadiri N, Abadi SS, Mesgarpour B, Goudarzi H, et al. Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis. J Bras Pneumol. 2022;48:e20210384.
doi: 10.36416/1806-3756/e20210384
pubmed: 35649043
Lv L, Li T, Xu K, Shi P, He B, Kong W, et al. Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis. Infect Drug Resist. 2018;11:147–54.
doi: 10.2147/IDR.S153499
pubmed: 29416359
Basit A, Ahmad N, Khan AH, Javaid A, Syed Sulaiman SA, Afridi AK, et al. Predictors of two months culture conversion in multidrug-resistant tuberculosis: findings from a retrospective cohort study. PLoS ONE. 2014;9(4):e93206.
doi: 10.1371/journal.pone.0093206
pubmed: 24705411
Ahmad Khan F, Salim MAH, Du Cros P, Casas EC, Khamraev A, Sikhondze W, et al. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses. Eur Respir J. 2017;50(1):1700061.
doi: 10.1183/13993003.00061-2017
pubmed: 28751411
Tong E, Wu Q, Chen Y, Liu Z, Zhang M, Zhu Y, et al. The efficacy and safety of Bedaquiline in the treatment of pulmonary tuberculosis patients: a systematic review and Meta-analysis. Antibiotics. 2023;12(9):1389.
doi: 10.3390/antibiotics12091389
pubmed: 37760686
Zhang X, Falagas ME, Vardakas KZ, Wang R, Qin R, Wang J, et al. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis. 2015;7(4):603–15.
pubmed: 25973226
Nasiri MJ, Zangiabadian M, Arabpour E, Amini S, Khalili F, Centis R, et al. Delamanid-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis. Int J Infect Dis. 2022;124:S90–103.
doi: 10.1016/j.ijid.2022.02.043
pubmed: 35245659
Labuda SM, Seaworth B, Dasgupta S, Goswami ND. Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis. Lancet Respir Med. 2024;12(2):e5–6.
doi: 10.1016/S2213-2600(23)00426-5
pubmed: 38043563
Van De Berg SEJ, Pelzer PT, Van Der Land AJ, Abdrakhmanova E, Ozi AM, Arias M, et al. Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients. BMC Public Health. 2021;21(1):1404.
doi: 10.1186/s12889-021-11427-y
pubmed: 34271884
Sweeney S, Berry C, Kazounis E, Motta I, Vassall A, Dodd M, et al. Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis. Muniyandi M, editor. PLOS Glob Public Health. 2022;2(12):e0001337.
doi: 10.1371/journal.pgph.0001337
pubmed: 36962909